Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Sponsors And FDA: Will Better Communication Under PDUFA V Ease Inherent Tensions?

Executive Summary

New communication mechanisms built into the Prescription Drug User Fee Act V agreement are unlikely to be the panacea for the regulatory, economic and public relations challenges created when a small company attempts to bring its first drug to market.


Related Content

If At First You Don’t Succeed, Try Dispute Resolution
Breakthrough Products Should Be Free Of PDUFA Constraints, Sponsors Say
Theravance’s Persistence On Telavancin Rewarded With Positive Cmte. Vote
Orexigen Eyes Earlier Resubmission Of Contrave NDA
Orexigen Eyes Earlier Resubmission Of Contrave NDA
Bydureon Review Documents Paint An Unflattering Portrait Of Amylin
“Emerging Sponsors” Pose Regulatory, Public Relations Challenges For Drug Review Process, FDA’s Jenkins Says
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle
Acorda Builds Ampyra Promotion On Years Of MS Outreach


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts